Skip to main
GMED

Globus Medical (GMED) Stock Forecast & Price Target

Globus Medical (GMED) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 42%
Buy 42%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Globus Medical Inc. is positioned for a positive financial outlook, driven by anticipated growth in the spine market and an increase in sales from enabling technologies, with adjustments indicating a potential 3% rise in revenue. The company's fourth-quarter performance showcased a robust 10% growth in Nevro, emphasizing strong core spine performance in the U.S., while organic growth is expected to improve, possibly exceeding revenue guidance. Additionally, the expectation of stabilization in EBITDA margins around 34-35% in 2026, along with strong free cash flow and strategic balance sheet management, underlines the firm's potential for operational efficiency and profitability enhancement.

Bears say

Globus Medical faces significant risks that could negatively impact its financial performance, including slower growth in the spine market and potential revenue disruptions from the mergers of NuVasive and Nevro. The bear case scenario projects revenue growth could decelerate to low single digits with flat margins, while various factors, such as competitive dynamics and underperforming product launches, pose further risks to growth. Additionally, challenges in expanding into new musculoskeletal markets and a declining capital environment for robotic purchases could adversely affect the company's operating margins and overall financial outlook.

Globus Medical (GMED) has been analyzed by 12 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 42% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Globus Medical (GMED) Forecast

Analysts have given Globus Medical (GMED) a Buy based on their latest research and market trends.

According to 12 analysts, Globus Medical (GMED) has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $96.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $96.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Globus Medical (GMED)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.